~~<i id='2ED222BF36'><strike id='2ED222BF36'><tt id='2ED222BF36'><pre id='2ED222BF36'></pre></tt></strike></i>~~

Home» knowledge» leisure time

leisure time

author：explore 2025-10-06 09:26:38 Page View：844

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novartis is flashing warning signs about its newly acquired myelofibrosis drug
Next article： Duchenne breakthrough therapy leaves behind pioneering families

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

Sutter Health’s antitrust win overturned by appeals court

AdobeWhenSutterHealthwasontrialforanticompetitiveconductin2022,theSanFranciscojurymissedoutonsomecru

Affirmative action in medical school literally saved lives

AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

BD to buy Edwards patient monitoring unit for $4.2 billion

IanWaldie/GettyImagesBectonDickinsonplanstopay$4.2billionforEdwardsLifesciences’criticalcarebusiness